Navigation Links
Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
Date:10/27/2011

ime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing, scope and outcomes of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial enrollment and results, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
2. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
3. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
4. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
7. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
8. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
9. Halozyme Receives $5.5 Million Payment From Baxter
10. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
11. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... July 31 InNexus,Biotechnology Inc., (TSX VENTURE: ... a drug development company commercializing the,next generation ... Cross Linking,(DXL(TM)) technology, will present at IBC,s ... of Innovative Therapeutics (DDT) Conference being,held in ...
... BERKELEY HEIGHTS, N.J., July 31 Genta,Incorporated (OTC ... release its second quarter 2008 financial results on ... conference call and live audio,webcast to discuss these ... Participants can access the live call by ...
... Amicus Therapeutics,(Nasdaq: FOLD ), a biopharmaceutical company ... of human,genetic diseases, will announce second quarter 2008 ... Thursday, August 7, 2008. The results,announcement will be ... that,afternoon at 5 p.m. EDT., Interested participants ...
Cached Biology Technology:InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 3Amicus Therapeutics Announces Second Quarter 2008 Results Release Date 2
(Date:7/11/2014)... American Society for Bone and Mineral Research awarded Michael ... Medicine (BUSM), with the 2014 Louis V. Avioli Award. ... BUSM, is internationally known for revolutionizing the understanding of ... , The award honors a member of the American ... contributions to bone and mineral basic research. It is ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... that remains unusually stable in the body, researchers at ... to the development of therapeutic RNA nanotechnology. Peixuan ... and professor of biomedical engineering, and his colleagues in ... construction of a thermodynamically stable RNA nanoparticle online in ...
... it turns out, suppresses melatonin 5 times more than exposure ... off an orange-yellow light. "Just as there are regulations and ... rules for the pollution stemming from artificial light at night," ... "White" light bulbs that emit light at shorter wavelengths ...
... Findings, published today in Nature and ... Pressure Genome-Wide Association Studies represent a major advance in our ... new potential therapeutic targets for prevention of heart disease and ... Research published in Nature and co-led by scientists ...
Cached Biology News:Team finds stable RNA nano-scaffold within virus core 2Dangers of exposure to 'white' light 2Dangers of exposure to 'white' light 3Discovery of blood pressure genes could help prevent cardiovascular disease 2Discovery of blood pressure genes could help prevent cardiovascular disease 3
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
NORMAL DONOR DONKEY SERUM...
... Molecular Probes Fc OxyBURST Green reagent (F-2902) ... of Boston University to permit measurement of ... and the subsequent oxidative burst directly in ... reagent consists of bovine serum albumin (BSA) ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
Biology Products: